Merck & Co Inc (NYSE: MRK) has reported E.P.S. of $1.24 for its third fiscal quarter (ending September 30) versus $1.87 for the same period a year ago — a decline of -34%. For the latest four quarters through September 30, E.P.S. were $4.78 compared to $1.81 a year ago — an increase of 164%.
Recent Price Action
Merck & Co Inc (NYSE: MRK) stock closed at $102.32 on 10/31/24 after a decline of -2.4%. Moreover, unusually high trading volume at 186% of normal accompanied the decline. The stock has declined -3.8% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
MRK is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Merck has a current Value Trend Rating of C (Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Merck has a slightly positive Appreciation Score of 70 but a slightly negative Power Rating of 37, producing the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment